NBY NovaBay Pharmaceuticals Inc.

1.01
-0.09  -8%
Previous Close 1.1
Open 1.1
Price To Book 3.48
Market Cap 17411697
Shares 17,239,304
Volume 3,253
Short Ratio 2.3
Av. Daily Volume 22,615

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data released August 2014. Endpoints not met
Auriclosene (NVC-422)
Viral conjunctivitis
Failed to meet endpoint Nov 2013. Plans to reinitiate trial in 2014
Auriclosene (NVC-422)
Impetigo skin infection study

Latest News

  1. NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication
  2. NovaBay Pharmaceuticals Announces New Partner Pharmacy Program
  3. NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results
  4. NovaBay Pharmaceuticals, Inc. to Host Earnings Call
  5. NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy
  6. Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for
  7. NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance
  8. NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results
  9. NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018
  10. Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know
  11. NovaBay Pharmaceuticals Names Jack McGovern Interim CEO
  12. NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
  13. NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results
  14. NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
  15. NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth
  16. NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results
  17. NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018